Carbetocin (Duratocin / Pabal / Lonactene)
Long-acting synthetic oxytocin analog used for prevention of postpartum hemorrhage; recently FDA-approved for that indication.
At a glance
What it is: Long-acting synthetic oxytocin analog used for prevention of postpartum hemorrhage; recently FDA-approved for that indication..
Primary research applications:
- Prevention of postpartum hemorrhage after cesarean delivery (FDA-approved indication, 2023)
- Postpartum hemorrhage prevention more broadly (approved internationally for years)
- Research interest in social cognition and Prader-Willi behavioral symptoms
Editorial summary: Carbetocin is a long-acting oxytocin analog originally approved internationally for postpartum hemorrhage prevention and gaining wider attention after FDA approval (2023, room-temperature stable formulation). Its longer half-life vs. native oxytocin and improved thermal stability make it operationally distinct from oxytocin, and it is being studied separately in social-cognition and behavioral-symptom research where intranasal oxytocin work has been mixed.
- Class / structure
- Synthetic oxytocin analog with deamination and methylation of the cysteine bridge
- Half-life
- ~30–40 minutes (vs. ~3–5 minutes for oxytocin)
- First described
- Synthesized 1980s; international approval over the 1990s; FDA approval 2023
- Regulatory status
- FDA-approved 2023 (room-temperature-stable formulation); approved in many countries since the 1990s
What is Carbetocin?
Carbetocin is a synthetic oxytocin analog with structural modifications that confer extended half-life and improved stability while preserving oxytocin receptor binding and uterotonic activity. Its primary clinical use is prevention of postpartum hemorrhage.[1]
Discovery and development
Carbetocin was synthesized as a longer-acting oxytocin analog with greater stability through structural modifications to the disulfide bridge of native oxytocin. International approval for postpartum hemorrhage prevention came through the 1990s and 2000s, with use widespread in Europe and Canada under the Duratocin and Pabal brand names.
The FDA approval in 2023 (under the brand Lonactene for cesarean-delivery use) is significant because it covers a heat-stable formulation that does not require cold-chain storage — operationally important for global maternal-health programs in resource-limited settings where reliable refrigeration is not assured.
Mechanism of action
Binds the oxytocin receptor on uterine smooth muscle, producing sustained contraction and reducing post-delivery uterine bleeding. The longer half-life vs. oxytocin allows the same hemostatic effect from a single dose that would otherwise require continuous infusion.
Pharmacokinetics
IV or IM administration with half-life around 30–40 minutes — substantially longer than native oxytocin (3–5 minutes), allowing single-dose administration rather than continuous infusion for postpartum hemorrhage prevention.
What the research shows
The peer-reviewed literature on Carbetocin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Prevents postpartum hemorrhage as effectively as oxytocin | Phase 3 evidence | Established |
| Useful in resource-limited settings due to thermal stability | WHO CHAMPION trial evidence | Established |
| Treats Prader-Willi behavioral symptoms (intranasal) | Mixed Phase 2/3 data; ongoing investigation | Preliminary |
| Equivalent to oxytocin for social-cognition research | Different PK; not a settled question | Uncertain |
Reported user experiences
How the research describes administration
For postpartum hemorrhage prevention: single 100 µg IV or IM dose after delivery. For research uses: protocol-specific.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Carbetocin is a quietly important pharmaceutical — a long-acting oxytocin analog whose role in postpartum hemorrhage prevention is well-established and whose heat-stable formulation has meaningful global health implications. Its potential for social-cognition or Prader-Willi behavioral applications is interesting but at much lower evidence-strength tier than the established obstetric use.
Frequently asked questions
How is carbetocin different from oxytocin?
Same receptor target and same uterotonic effect, but carbetocin's half-life is roughly 10× longer (30–40 minutes vs. 3–5 minutes), allowing single-dose administration where oxytocin would require infusion. The heat-stable carbetocin formulation also doesn't require cold-chain storage — operationally important for global health programs.
Is intranasal carbetocin used for social cognition like intranasal oxytocin?
It's been investigated, particularly in Prader-Willi syndrome where hyperphagia and behavioral symptoms are major concerns. The early data is mixed and the field shares the methodological challenges of intranasal oxytocin research more broadly. Treat the social-cognition framing with appropriate caution.
Why did carbetocin get FDA approval recently when it was already approved internationally?
The 2023 FDA approval covers a specific room-temperature-stable formulation supported by the WHO CHAMPION trial data. The molecule itself has been approved internationally (under brand names like Duratocin and Pabal) since the 1990s.
References
- Hunter DJ, et al. Carbetocin: a synthetic analog of oxytocin. Br J Pharmacol. 1992;105(2):440-444. https://pubmed.ncbi.nlm.nih.gov/1314588/
- Widmer M, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. N Engl J Med. 2018;379(8):743-752. https://pubmed.ncbi.nlm.nih.gov/29949473/
- Voon HY, et al. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: a meta-analysis of randomized controlled trials. Obstet Gynecol. 2018;131(4):700-710. https://pubmed.ncbi.nlm.nih.gov/29528137/
- Roof E, et al. Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi syndrome. JCI Insight. 2023;8(7):e168298. https://pubmed.ncbi.nlm.nih.gov/37027316/